One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.

J Bone Miner Res. 2018 Dec 3. doi: 10.1002/jbmr.3622. [Epub ahead of print]

DOI: 10.1002/jbmr.3622  -PMID: 30508316

Lewiecki EM(1), Dinavahi RV(2), Lazaretti-Castro M(3), Ebeling PR(4), Adachi JD(5), Miyauchi A(6), Gielen E(7), Milmont CE(2), Libanati C(8), Grauer A(2).

https://www.ncbi.nlm.nih.gov/pubmed/30508316
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen